Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Enterprise Value: -98.31M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -98.31M |
| May 16, 2024 | -95.36M |
| May 15, 2024 | -100.61M |
| May 14, 2024 | -105.94M |
| May 13, 2024 | -97.66M |
| May 10, 2024 | -97.66M |
| May 09, 2024 | -100.90M |
| May 08, 2024 | -98.97M |
| May 07, 2024 | -102.58M |
| May 06, 2024 | -103.90M |
| May 03, 2024 | -91.74M |
| May 02, 2024 | -98.81M |
| May 01, 2024 | -95.36M |
| April 30, 2024 | -98.28M |
| April 29, 2024 | -100.94M |
| April 26, 2024 | -95.03M |
| April 25, 2024 | -95.03M |
| April 24, 2024 | -95.03M |
| April 23, 2024 | -95.03M |
| April 22, 2024 | -95.03M |
| April 19, 2024 | -113.43M |
| April 18, 2024 | -99.63M |
| April 17, 2024 | -94.04M |
| April 16, 2024 | -94.04M |
| April 15, 2024 | -92.73M |
| Date | Value |
|---|---|
| April 12, 2024 | -92.73M |
| April 11, 2024 | -95.68M |
| April 10, 2024 | -89.11M |
| April 09, 2024 | -92.40M |
| April 08, 2024 | -92.40M |
| April 05, 2024 | -92.73M |
| April 04, 2024 | -94.04M |
| April 03, 2024 | -89.52M |
| April 02, 2024 | -94.37M |
| April 01, 2024 | -84.51M |
| March 28, 2024 | -84.51M |
| March 27, 2024 | -84.51M |
| March 26, 2024 | -83.20M |
| March 25, 2024 | -85.17M |
| March 22, 2024 | -88.95M |
| March 21, 2024 | -95.03M |
| March 20, 2024 | -95.03M |
| March 19, 2024 | -95.35M |
| March 18, 2024 | -85.00M |
| March 15, 2024 | -92.40M |
| March 14, 2024 | -95.52M |
| March 13, 2024 | -99.96M |
| March 12, 2024 | -91.26M |
| March 11, 2024 | -87.31M |
| March 08, 2024 | -85.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-127.57M
Minimum
May 11 2022
884.52M
Maximum
Jan 14 2022
89.77M
Average
-45.36M
Median
Oct 03 2022
Enterprise Value Benchmarks
| AC Immune SA | 198.33M |
| CRISPR Therapeutics AG | 2.666B |
| Addex Therapeutics Ltd | 4.792M |
| NLS Pharmaceutics Ltd | 7.841M |
| MoonLake Immunotherapeutics | 1.962B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.32M |
| Revenue (Quarterly) | 1.164M |
| Total Expenses (Quarterly) | 19.95M |
| EPS Diluted (Quarterly) | -0.677 |
| Profit Margin (Quarterly) | -1.92K% |
| Earnings Yield | -55.67% |
| Normalized Earnings Yield | -51.07 |